Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials

[1]  M. A. van de Laar,et al.  Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: A placebo-controlled, ex vivo, serial placebo-controlled serial crossover study , 2012, European Journal of Clinical Pharmacology.

[2]  P. McGettigan,et al.  Cardiovascular Risk with Non-Steroidal Anti-Inflammatory Drugs: Systematic Review of Population-Based Controlled Observational Studies , 2011, PLoS medicine.

[3]  R. Shephard.  Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis , 2011 .

[4]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[5]  T. Grosser,et al.  Emotion recollected in tranquility: lessons learned from the COX-2 saga. , 2010, Annual review of medicine.

[6]  Chiu-Hsieh Hsu,et al.  Sulindac and Sulindac Metabolites in Nipple Aspirate Fluid and Effect on Drug Targets in a Phase I Trial , 2010, Cancer Prevention Research.

[7]  B. Gersh.  Cardiovascular Risk of Celecoxib in 6 Randomized Placebo-Controlled Trials: The Cross Trial Safety Analysis , 2009 .

[8]  L. G. García Rodríguez,et al.  Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. , 2008, Journal of the American College of Cardiology.

[9]  Deepak L. Bhatt,et al.  ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. , 2008, Circulation.

[10]  S. Solomon,et al.  Cardiovascular Risk of Celecoxib in 6 Randomized Placebo-Controlled Trials: The Cross Trial Safety Analysis , 2008, Circulation.

[11]  Sanjay Kaul,et al.  ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. , 2008, Journal of the American College of Cardiology.

[12]  L. Di Francesco,et al.  Human Pharmacology of Naproxen Sodium , 2007, Journal of Pharmacology and Experimental Therapeutics.

[13]  P. Tugwell,et al.  Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[14]  J. Emberson,et al.  Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials , 2006, BMJ : British Medical Journal.

[15]  D G Altman,et al.  Indirect comparisons of competing interventions. , 2005, Health technology assessment.

[16]  E. Ricciotti,et al.  Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. , 2005, Journal of the American College of Cardiology.

[17]  Robert Riddell,et al.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. , 2005, The New England journal of medicine.

[18]  Andreas Hoeft,et al.  Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. , 2005, The New England journal of medicine.

[19]  Marc A Pfeffer,et al.  Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention , 2005, The New England journal of medicine.

[20]  F. N. Sarabia,et al.  Comparison of aceclofenac with piroxicam in the treatment of osteoarthritis , 1997, Clinical Rheumatology.

[21]  F. Perez-Ruiz,et al.  Comparative study of the efficacy and safety of Aceclofenac and Tenoxicam in rheumatoid arthritis , 1996, Clinical Rheumatology.

[22]  F. Gribnau,et al.  A comparison of diflunisal and phenylbutazone in the treatment of ankylosing spondylitis , 1986, Clinical Rheumatology.

[23]  A. Chopra,et al.  Randomized double-blind clinical drug trials of meloxicam in rheumatoid arthritis and osteoarthritis knees: an Indian experience , 2004 .

[24]  T. Schnitzer,et al.  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial , 2004, The Lancet.

[25]  C. Patrono,et al.  Clinical Pharmacology of Platelet, Monocyte, and Vascular Cyclooxygenase Inhibition by Naproxen and Low-Dose Aspirin in Healthy Subjects , 2004, Circulation.

[26]  E. Martı́n-Mola,et al.  Aceclofenac in comparison to ketoprofen in the treatment of rheumatoid arthritis , 2004, Rheumatology International.

[27]  A. Raber,et al.  The efficacy and tolerability of aceclofenac compared to indomethacin in patients with rheumatoid arthritis , 2004, Rheumatology International.

[28]  R. Dreiser.  A comparison of the efficacy of etodolac SR (Lodine® SR) and etodolac (Lodine®) in patients with rheumatoid arthritis or osteoarthritis , 2004, Rheumatology International.

[29]  G. Naglie,et al.  The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. , 2003, Arthritis and rheumatism.

[30]  P. Duke,et al.  Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. , 2003, The Journal of thoracic and cardiovascular surgery.

[31]  Douglas G Altman,et al.  Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses , 2003, BMJ : British Medical Journal.

[32]  P. Shekelle,et al.  A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. , 2002, The Journal of rheumatology.

[33]  Karen A Robinson,et al.  Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. , 2002, International journal of epidemiology.

[34]  Jian-hua Xu.  A double-blind,randomized controlled clinical study of meloxicam and nabumetone in the treatment of rheumatoid arthritis , 2002 .

[35]  C. Chou,et al.  A double-blind, randomized, controlled parallel group study evaluating the efficacy and safety of acemetacin for the management of osteoarthritis. , 2002, International journal of clinical pharmacology research.

[36]  T. Burnakis.  Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. , 2002, The New England journal of medicine.

[37]  S A Rich,et al.  The coxibs, selective inhibitors of cyclooxygenase-2. , 2001, The New England journal of medicine.

[38]  C. Nzerue.  The coxibs, selective inhibitors of cyclooxygenase-2. , 2001, The New England journal of medicine.

[39]  C.-T. Hsu,et al.  Endoscopic Comparison of the Gastroduodenal Safety and the Effects on Arachidonic Acid Products between Meloxicam and Piroxicam in the Treatment of Osteoarthritis , 2001, Clinical Rheumatology.

[40]  R Day,et al.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. , 2000, The New England journal of medicine.

[41]  Palmer,et al.  Safety and efficacy of nabumetone in osteoarthritis: emphasis on gastrointestinal safety , 2000, Alimentary pharmacology & therapeutics.

[42]  Lise,et al.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. , 2000, The New England journal of medicine.

[43]  B. Dhaon,et al.  Comparative efficacy and tolerability of nimesulide and piroxicam in osteoarthritis with specific reference to chondroprotection: a double blind randomised study. , 1999, Journal of the Indian Medical Association.

[44]  S. Rastogi,et al.  Comparative efficacy and safety of nimesulide versus piroxicam in osteoarthritis with special reference to chondroprotection. , 1999, American journal of therapeutics.

[45]  C. Hawkey,et al.  Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis. , 1998, British journal of rheumatology.

[46]  C. M. Chukwuani,et al.  Comparative double blind study of the efficacy and safety of tenoxicam vs. piroxicam in osteoarthritis of knee and hip joints. , 1998, West African journal of medicine.

[47]  U. Serni,et al.  Efficacy and tolerability of ketoprofen 200 mg controlled-release cps vs indomethacin 50 mg cps in patients with symptomatic hip osteoarthritis. A multicentre study. , 1997, Minerva medica.

[48]  R. Lightfoot.  Comparison of the efficacy and safety of etodolac and piroxicam in patients with rheumatoid arthritis. Etodolac Study 326 Rheumatoid Arthritis Investigators Group. , 1997, The Journal of rheumatology. Supplement.

[49]  E. Bluhmki,et al.  A double-blind study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip. , 1996, British journal of rheumatology.

[50]  M. D. De Buergo,et al.  Aceclofenac is as safe and effective as tenoxicam in the treatment of ankylosing spondylitis: a 3 month multicenter comparative trial. Spanish Study Group on Aceclofenac in Ankylosing Spondylitis. , 1996, The Journal of rheumatology.

[51]  Walker,et al.  Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .

[52]  G. Perpignano,et al.  Double-blind comparison of the efficacy and safety of etodolac SR 600 mg u.i.d. and of tenoxicam 20 mg u.i.d. in elderly patients with osteoarthritis of the hip and of the knee. , 1994, International journal of clinical pharmacology research.

[53]  A. Burssens,et al.  Double-blind comparison of etodolac SR tablets and tenoxicam capsules in the treatment of osteoarthritis of the knee , 1993 .

[54]  P. Franchimont,et al.  Double-blind comparison of etodolac and piroxicam in the treatment of rheumatoid arthritis. , 1993, Clinical therapeutics.

[55]  R. Jubb,et al.  Double-blind comparison of etodolac sustained-release tablets and piroxicam capsules in patients with rheumatoid arthritis: An interim report , 1992 .

[56]  M. Poland,et al.  Nabumetone compared with indomethacin in the treatment of osteoarthritis in general practice. , 1992, The Journal of rheumatology. Supplement.

[57]  M. Al-Nahdi.  EFFICACY AND TOLERABILITY OF LONG-TERM TENOXICAM VERSUS PIROXICAM IN PATIENTS WITH RHEUMATOID ARTHRITIS OR OSTEOARTHRITIS , 1992 .

[58]  W. Dick,et al.  Safety and efficacy of etodolac compared with piroxicam in patients with degenerative joint disease of the knee. , 1992, Clinical therapeutics.

[59]  A. Calin,et al.  A comparison of the efficacy and tolerability of lornoxicam and indomethacin in ankylosing spondylitis , 1992 .

[60]  K. Brandt,et al.  Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. , 1991, The New England journal of medicine.

[61]  G. Porro,et al.  Endoscopic Assessment of Tenoxicam- and Piroxicam-Induced Lesions in Osteoarthritic Patients , 1991 .

[62]  D. Briançon,et al.  Double-blind parallel-group evaluation of the safety and efficacy of etodolac capsules compared with piroxicam capsules in patients with rheumatoid arthritis , 1991 .

[63]  S. Mendelsohn.  Clinical efficacy and tolerability of naproxen in osteoarthritis patients using twice-daily and once-daily regimens , 1991 .

[64]  C. Díaz-López,et al.  Comparative double-blind study of droxicam (new NSAID) versus indomethacin in rheumatoid arthritis. , 1991, European journal of rheumatology and inflammation.

[65]  C. Reuter,et al.  Therapeutic activity, clinical and gastric tolerance of 20mg daily dose of droxicam in comparison with piroxicam in patients with degenerative joint disease. , 1991, European journal of rheumatology and inflammation.

[66]  A double-blind randomised controlled trial of droxicam versus indomethacin in rheumatoid arthritis. , 1991, European journal of rheumatology and inflammation.

[67]  M. Schattenkirchner.  Double-blind comparison of etodolac and piroxicam in patients with rheumatoid arthritis. , 1991, Current medical research and opinion.

[68]  A. Karbowski,et al.  Double-blind, parallel comparison of etodolac and indomethacin in patients with osteoarthritis of the knee. , 1991, Current medical research and opinion.

[69]  G. Astorga Paulsen,et al.  Efficacy and tolerability comparison of etodolac and piroxicam in the treatment of patients with osteoarthritis of the knee. , 1991, Current medical research and opinion.

[70]  C. Oliani,et al.  Efficacy and gastrointestinal tolerability of beta-cyclodextrin-piroxicam and tenoxicam in the treatment of chronic osteoarthritis. , 1990, Clinical therapeutics.

[71]  L. Pučar,et al.  Efficacy of Tenoxicam in the Treatment of Patients with Rheumatoid Arthritis , 1990 .

[72]  F. I. Lee,et al.  Double-Blind Evaluation of the Safety and Efficacy of Tenoxicam (Tilcotil®) Compared with Piroxicam in Patients with Degenerative Arthritis , 1990 .

[73]  C. Amante.  Tenoxicam Versus Piroxicam in Rheumatoid Arthritis , 1990 .

[74]  G. G. Freitas.  A double-blind comparison of etodolac and piroxicam in the treatment of osteoarthritis. , 1990, Current medical research and opinion.

[75]  V. Jamieson,et al.  A large multicentre, parallel group, double‐blind study comparing tenoxicam and piroxicam in the treatment of osteoarthritis and rheumatoid arthritis , 1989, The British journal of clinical practice.

[76]  K. O’Brien,et al.  A comparison of the effects of tenoxicam and piroxicam on grip strength in patients with rheumatoid arthritis. , 1989, Scandinavian journal of rheumatology. Supplement.

[77]  L. Ejstrup,et al.  A randomised double-blind multicentre trial comparing tenoxicam and ketoprofen in osteoarthritis. , 1989, Scandinavian journal of rheumatology. Supplement.

[78]  P. Tsachalos,et al.  Long-term (four year) clinical trial with tenoxicam and basis therapy in patients suffering from rheumatoid arthritis. , 1989, Scandinavian journal of rheumatology. Supplement.

[79]  Caldwell,et al.  Ketoprofen versus indomethacin in patients with rheumatoid arthritis: a multicenter double blind comparative study. , 1988, The Journal of rheumatology.

[80]  P. Lee,et al.  The efficacy and safety of sulindac (400 mg vs 600 mg daily) in rheumatoid arthritis. A Canadian Multicentre Study. , 1988, The Journal of rheumatology.

[81]  A. Dixon,et al.  A prospective endoscopic study of the effect of Orudis and Oruvail on the upper gastrointestinal tract, in patients with osteoarthritis. , 1988, British journal of rheumatology.

[82]  A. Chivabongs.  Controlled-release ketoprofen in rheumatoid arthritis and osteoarthritis: comparison of two doses in Thailand. , 1988, Clinical therapeutics.

[83]  J. Kryger,et al.  A long-term randomised trial on tenoxicam and piroxicam in osteoarthritis of the hip or knee: a 24-month interim report focusing on the 12-24 month interval. , 1987, European journal of rheumatology and inflammation.

[84]  G. Astorga.  Double-blind, parallel clinical trial of tenoxicam (Ro 12-0068) versus piroxicam in patients with ankylosing spondylitis. , 1987, European journal of rheumatology and inflammation.

[85]  D. Rice.  Comparison of diflunisal and piroxicam in the management of patients with rheumatoid arthritis. , 1987, Clinical therapeutics.

[86]  H. Havranek.  Double-blind study of tenoxicam 20 mg versus piroxicam 20 mg in rheumatoid arthritis. , 1987, European journal of rheumatology and inflammation.

[87]  A. Sidi,et al.  Long-term study with tenoxicam (Ro 12-0068) in the treatment of gonarthrosis and coxarthrosis. , 1987, European journal of rheumatology and inflammation.

[88]  N. Bellamy,et al.  Double-blind randomized controlled trial of isoxicam vs piroxicam in elderly patients with osteoarthritis of the hip and knee. , 1986, British journal of clinical pharmacology.

[89]  V. Wright,et al.  A parallel group comparison of tenoxicam and piroxicam in patients with ankylosing spondylitis. , 1986, Pharmatherapeutica.

[90]  A. Darke,et al.  Fecal blood loss during isoxicam and piroxicam administration for 28 days , 1985, Clinical pharmacology and therapeutics.

[91]  John D. Jessop,et al.  European double-blind multicenter study comparing isoxicam and indomethacin in treatment of degenerative joint disease. , 1985, The American journal of medicine.

[92]  Piroxicam vs indomethacin: a double blind multicenter comparative study in osteoarthritis. A Canadian Multicenter Study. , 1985, The Journal of rheumatology.

[93]  V. Wright,et al.  A comparison of faecal blood loss caused by tenoxicam and piroxicam in normal healthy male volunteers. , 1985, Current medical research and opinion.

[94]  V. Wright,et al.  A double-blind parallel study of tenoxicam and piroxicam in patients with osteoarthrosis. , 1985, European journal of rheumatology and inflammation.

[95]  K. Taylor,et al.  A comparison of tenoxicam and piroxicam in a long-term clinical study in patients with osteoarthritis of hip or knee joints. , 1985, European journal of rheumatology and inflammation.

[96]  W. Standel,et al.  Clinical evaluation of tenoxicam in osteoarthrosis, rheumatoid arthritis and ankylosing spondylitis. , 1985, European journal of rheumatology and inflammation.

[97]  A. Gordin,et al.  Comparison of slow-release indomethacin and diflunisal in patients with arthrosis. , 1984, Current medical research and opinion.

[98]  T. Videman,et al.  Double-blind parallel study of piroxicam versus indomethacin in the treatment of low back pain. , 1984, Annals of clinical research.

[99]  P. Franchimont,et al.  Clinical Trial of Pirprofen in Arthrosis of the Knee Joint: A Double-Blind Comparison with Indomethacin , 1983, The Journal of international medical research.

[100]  Phillip Janke,et al.  Sulindac versus piroxicam in the treatment of osteoarthritis. , 1983, Current medical research and opinion.

[101]  J. H. Young,et al.  'Osmosin' in general practice: preliminary report of a double-blind study in the treatment of osteoarthritis. , 1983, Current medical research and opinion.

[102]  D. Palmer,et al.  Oxaprozin and sulindac in rheumatoid arthritis: a double-blind comparative trial. , 1983, Current medical research and opinion.

[103]  J. Meurice.  Treatment of osteoarthritis: a 3-month comparison between tiaprofenic acid and indomethacin. , 1983, Current medical research and opinion.

[104]  H. Mattern,et al.  European double-blind multicenter study comparing meclofenamate sodium and indomethacin in the treatment of rheumatoid arthritis. , 1983, Arzneimittel-Forschung.

[105]  W. Ebner,et al.  Meclofenamate sodium in the treatment of ankylosing spondylitis. Report of a European double-blind controlled multicenter study. , 1983, Arzneimittel-Forschung.

[106]  Muller-Fassbender Hh,et al.  Comparative study of piroxicam and indomethacin retard in osteoarthritis. , 1983, European journal of rheumatology and inflammation.

[107]  R. T. Reid,et al.  Long-term, double-blind, randomized parallel group studies comparing fenbufen with indometacin in patients with osteoarthritis. , 1982, Pharmacology.

[108]  K. Shichikawa,et al.  [A double-blind multi-center clinical trial of benoxaprofen against indomethacin in rheumatoid arthritis (author's transl)]. , 1982, Ryumachi. [Rheumatism].

[109]  T. Juvakoski,et al.  A double-blind cross-over evaluation of ketoprofen and indomethacin in Reiter's disease. , 1982, Scandinavian journal of rheumatology.

[110]  J. Villiaumey,et al.  A comparative study of benoxaprofen and ketoprofen in ankylosing spondylitis. , 1982, European journal of rheumatology and inflammation.

[111]  A. L. Chodock.  Crossover comparison of benoxaprofen and indomethacin in rheumatoid arthritis and osteoarthritis. , 1982, European journal of rheumatology and inflammation.

[112]  G. Bach.  Activated osteoarthrosis (osteoarthritis) and its treatment with indomethacin and benoxaprofen: a double-blind crossover study. , 1982, European journal of rheumatology and inflammation.

[113]  S. Roth.  A comparison of benoxaprofen and sulindac in patients with rheumatoid arthritis and osteoarthritis. , 1982, European journal of rheumatology and inflammation.

[114]  P. Franchimont,et al.  A double-blind crossover study of benoxaprofen and indomethacin in outpatients suffering from osteoarthrosis of knees. , 1982, European journal of rheumatology and inflammation.

[115]  Joan Davies,et al.  A double blind cross-over comparison of piroxicam and indomethacin in the treatment of rheumatoid arthritis. , 1981, European journal of rheumatology and inflammation.

[116]  J. del Campo.  Double-blind multicentre, between patients comparison of indoprofen and indomethacin in rheumatoid arthritis patients under basic steroid treatment. , 1981, European journal of rheumatology and inflammation.

[117]  R. Finstad.  A Double‐Blind, Crossover, Multicentre Study of Piroxicam and Indomethacin in the Treatment of Rheumatoid Arthritis , 1981, The British journal of clinical practice.

[118]  I. Bahous.  Double-blind multicentre, between patients comparison of two different doses of indoprofen and one of indomethacin in osteoarthritis. , 1981, European journal of rheumatology and inflammation.

[119]  L. Tétreault,et al.  Comparative evaluation of carprofen and indomethacin in rheumatoid patients. , 1980, International journal of clinical pharmacology, therapy, and toxicology.

[120]  Bryan Paul Wordsworth,et al.  A double-blind cross-over trial of fenoprofen and phenylbutazone in ankylosing spondylitis. , 1980, Rheumatology and rehabilitation.

[121]  T. Gibson,et al.  Sulindac and indomethacin in the treatment of ankylosing spondylitis: a double-blind cross-over study. , 1980, Rheumatology and rehabilitation.

[122]  P. H. Petersen,et al.  A double-blind study comparing sulindac with indomethacin in rheumatoid arthritis. , 1980, Scandinavian journal of rheumatology. Supplement.

[123]  [Clinical evaluation of piroxicam in rheumatoid arthritis by double blind comparative multi-center studies]. , 1980, Ryumachi. [Rheumatism].

[124]  V. Rhind,et al.  A comparative study of benoxaprofen and indomethacin in ankylosing spondylitis. , 1980, The Journal of rheumatology. Supplement.

[125]  G. Gothoni,et al.  Tolfenamic acid in ankylosing spondylarthritis: a double-blind comparison to indomethacin. , 1980, Scandinavian journal of rheumatology. Supplement.

[126]  Proquazone ('Biarison') in osteoarthritis of the knee: a double-blind, dose comparison trial. , 1980, Pharmatherapeutica.

[127]  K. Shichikawa,et al.  [Clinical evaluation of feprazone in rheumatoid arthritis (author's transl)]. , 1979, Ryumachi. [Rheumatism].

[128]  K. Shichikawa,et al.  [A multicenter trial of sulindac in rheumatoid arthritis (author's transl)]. , 1979, Ryumachi. [Rheumatism].

[129]  F. Ammitzbøll.  Fenbufen and indomethacin in the treatment of rheumatoid arthritis. A comparative double-blind, crossover study. , 1979, Scandinavian journal of rheumatology. Supplement.

[130]  S. Deodhar,et al.  A comparative study of fenbufen and indomethacin in patients with rheumatoid arthritis. , 1979, Current medical research and opinion.

[131]  J. Fraser,et al.  TREATMENT OF EARLY BREAST CANCER , 1978, The Lancet.

[132]  D. Palmer,et al.  Fenbufen compared with indomethacin in osteoarthrosis. , 1978, Current medical research and opinion.

[133]  R. Grahame,et al.  A trial of feprazone in ankylosing spondylitis. , 1977, Rheumatology and rehabilitation.

[134]  G. Manz,et al.  Comparison of fenoprofen and oxyphenbutazone in patients with rheumatoid arthritis. , 1977, Current therapeutic research, clinical and experimental.

[135]  B. Greenberg,et al.  A Comparative Clinical Trial of Fenbufen and Indomethacin in Patients with Rheumatoid Arthritis , 1976, The Journal of international medical research.

[136]  N. Cardoe.  Double-blind cross-over study of ketoprofen and phenylbutazone in patients with chronic osteoarthrosis of the hip. , 1976, Rheumatology and rehabilitation.

[137]  J. Jessop.  Double-blind study of ketoprofen and phenylbutazone in ankylosing spondylitis. , 1976, Rheumatology and rehabilitation.

[138]  R. Wheeldon,et al.  Treatment of rheumatoid arthritis with tolmetin: a comparison with alclofenac. , 1976, Current medical research and opinion.

[139]  R. Parker,et al.  Long-term study of indomethacin and alclofenac in treatment of rheumatoid arthritis. , 1975, British medical journal.

[140]  M. Chamberlain,et al.  A double blind trial to assess the value of alclofenac compared with phenylbutazone in the management of rheumatoid arthritis. , 1975, Annals of the rheumatic diseases.

[141]  S. de la Cruz,et al.  Effect of ibuprofen dosage on patient response in rheumatoid arthritis. , 1975, Arthritis and rheumatism.

[142]  R. Desproges-Gotteron,et al.  A double-blind comparison of alclofenac and indomethacin in osteoarthritis of the hip. , 1971, Current therapeutic research, clinical and experimental.

[143]  S. Thune.  Comparison of phenyl- and monophenylbutazone (Mobutazon), especially in respect to the incidence of side effects. A double-blind study. , 1967, Acta rheumatologica Scandinavica.

[144]  Comparison of Etodolac and Piroxicam in Patients with Osteoarthritis of the Hip or Knee A Prospective , Randomised , Double-Blind , Controlled Multicentre , .